Copy Number Variation (CNV) detection is a cornerstone technology in modern molecular diagnostics, enabling the identification of genomic deletions and duplications associated with genetic disorders, cancer, and developmental abnormalities. This comprehensive technical guide explains the principle of CNV analysis, sample requirements, mainstream detection methods such as MLPA, qPCR, array CGH, and next-generation sequencing, along with clinical applications and quality standards. Whether you are a clinician, researcher, or laboratory professional, this article provides the essential knowledge for selecting the right CNV testing strategy.
Technical Overview
Copy Number Variations (CNVs) are segments of DNA typically larger than 1 kilobase (kb) that are present in variable copy numbers compared to a reference genome. These structural variations include deletions, duplications, insertions, and complex rearrangements that can range from a few kilobases to several megabases in size. CNVs represent one of the most abundant forms of human genetic variation, covering a substantial portion of the genome and contributing significantly to phenotypic diversity as well as disease susceptibility.
CNVs play a critical role in human health and disease. Pathogenic copy number changes are known to cause well-characterized genomic disorders such as DiGeorge syndrome (22q11.2 deletion), Prader-Willi/Angelman syndromes (15q11-q13), Charcot-Marie-Tooth disease type 1A (PMP22 duplication), Duchenne muscular dystrophy (DMD deletions/duplications), and spinal muscular atrophy (SMN1 deletion). In oncology, CNVs such as HER2/ERBB2 amplification in breast cancer and EGFR amplification in glioblastoma directly influence therapeutic decisions. Accurate CNV detection is therefore essential for clinical diagnosis, risk assessment, treatment selection, and genetic counseling.
Modern CNV detection workflows combine advanced molecular biology techniques with sophisticated bioinformatics algorithms. Depending on the clinical question, laboratories may employ targeted approaches such as Multiplex Ligation-dependent Probe Amplification (MLPA) or quantitative PCR (qPCR), or genome-wide approaches such as chromosomal microarray analysis (CMA) and next-generation sequencing (NGS). Reputable CNV testing services are typically performed in laboratories accredited to ISO 15189 or ISO/IEC 17025 standards, ensuring analytical validity, reproducibility, and traceability of results.
Testing Samples
Whole Blood Samples
Peripheral blood collected in EDTA anticoagulant tubes is the most common sample type for CNV detection. A volume of 2-5 mL is generally sufficient for most applications. Genomic DNA is extracted and quality-controlled before analysis. Blood samples should be stored at 2-8°C and processed within 48-72 hours to preserve DNA integrity.
Buccal Swabs and Saliva
Non-invasive sampling methods such as buccal swabs and saliva collection are widely used, particularly for pediatric patients, carrier screening programs, and population studies. These samples yield adequate genomic DNA for MLPA, qPCR, and low-pass whole genome sequencing. Proper collection protocols are essential to avoid contamination with exogenous DNA.
Prenatal Samples
For prenatal CNV detection, laboratories analyze amniotic fluid (typically 10-20 mL), chorionic villus samples (CVS, 10-20 mg), or fetal DNA from cord blood. These samples are used for rapid aneuploidy detection and microdeletion/microduplication syndrome diagnosis. Prenatal testing must follow strict maternal cell contamination (MCC) testing protocols, and accredited laboratories perform testing in accordance with international guidelines from professional bodies.
FFPE Tissue Samples
Formalin-fixed paraffin-embedded (FFPE) tissue is the standard sample type for oncology CNV testing, such as HER2 amplification analysis in breast and gastric cancer. DNA extracted from FFPE tissue is often fragmented; therefore, validated extraction protocols and appropriate quality metrics are required. Tumor content above 20-30% is typically recommended for reliable copy number analysis.
Cell-Free DNA (cfDNA)
Circulating cell-free DNA from maternal plasma is used for non-invasive prenatal screening (NIPS/NIPT), while circulating tumor DNA (ctDNA) enables non-invasive assessment of copy number alterations in oncology. Low-pass whole genome sequencing of cfDNA allows genome-wide aneuploidy and segmental CNV detection.
Other Sample Types
Additional accepted sample types include dried blood spots, cultured amniocytes, fibroblasts, fresh or frozen tissue, and pre-extracted genomic DNA. Each sample type has specific quantity and quality requirements, typically a minimum of 200 ng-1 µg DNA with an A260/A280 ratio of 1.8-2.0.
Testing Items
CNV detection services encompass a broad range of analytical targets tailored to different clinical scenarios:
- Whole genome CNV profiling: detection of submicroscopic deletions and duplications across all chromosomes, typically at resolution levels of 10-100 kb depending on the platform
- Chromosomal aneuploidy detection: identification of trisomy 21, 18, 13, and sex chromosome aneuploidies
- Microdeletion/microduplication syndrome panels: targeted detection of known genomic disorders such as 22q11.2 deletion, 1p36 deletion, Williams syndrome, Miller-Dieker syndrome, and Cri-du-chat syndrome
- Single-gene CNV analysis: detection of exon-level deletions and duplications in disease genes such as DMD, SMN1/SMN2, PMP22, CYP21A2, and FMR1
- Oncology CNV biomarkers: HER2/ERBB2, EGFR, MET, MYC, CCND1, and MDM2 amplification status
- Pharmacogenomic CNVs: CYP2D6 gene copy number for drug metabolism profiling
- Carrier screening CNVs: detection of dosage changes in recessive disease genes for reproductive risk assessment
- Regions of homozygosity (ROH): detection via SNP array for consanguinity assessment and uniparental disomy (UPD) analysis
- Verify and confirm CNV results: orthogonal validation using an independent method such as qPCR or MLPA
Testing Methods
Multiplex Ligation-dependent Probe Amplification (MLPA)
MLPA is a multiplex PCR-based technique that can interrogate up to 50 genomic loci simultaneously. Each probe consists of two oligonucleotides that hybridize adjacently to the target sequence and are ligated only when both are correctly bound. The ligated probes are amplified with universal primers, and the relative peak areas in capillary electrophoresis reflect the copy number at each locus. MLPA offers single-exon resolution, making it the gold standard for detecting DMD deletions/duplications and targeted gene CNV analysis. It requires minimal DNA input (as low as 20-50 ng) and delivers results within 24-48 hours.
Quantitative Real-Time PCR (qPCR)
qPCR-based dosage analysis compares the amplification of a target locus against a reference gene using ΔΔCt calculations. It is a rapid, cost-effective method for validating CNVs or analyzing a limited number of targets. Real-time qPCR is widely used for HER2 gene amplification testing when tissue is limited and for confirming findings from screening platforms.
Array Comparative Genomic Hybridization (aCGH / Array CGH)
Array CGH compares differentially labeled patient and reference DNA hybridized onto thousands of genomic clones or oligonucleotide probes immobilized on a glass slide. Fluorescence ratios at each probe reveal relative copy gains or losses. Modern oligonucleotide arrays provide genome-wide coverage with resolution down to 10-50 kb and were established by international professional guidelines as a first-tier test for individuals with developmental delay, intellectual disability, autism spectrum disorders, and multiple congenital anomalies.
SNP Genotyping Arrays
SNP arrays combine copy number assessment with genotype information, enabling detection of copy-neutral aberrations such as uniparental disomy, regions of homozygosity, and mosaicism in addition to standard CNVs. The B-allele frequency (BAF) and log R ratio (LRR) metrics provide complementary evidence for copy number interpretation.
Next-Generation Sequencing (NGS) Based CNV Detection
NGS-based approaches infer CNVs from read-depth deviations across the genome or targeted regions. Low-pass whole genome sequencing (lpWGS, typically 0.1-1x coverage) is the foundation of non-invasive prenatal screening and provides 5-10 Mb resolution genome-wide aneuploidy and segmental CNV detection. Whole exome sequencing (WES) and targeted panel sequencing enable concurrent detection of sequence variants and exon-level CNVs using algorithms such as ExomeDepth, XHMM, and CNVkit, achieving a comprehensive one-test diagnostic strategy.
Digital PCR (dPCR)
Droplet digital PCR partitions the reaction into thousands of individual droplets, enabling absolute quantification of copy number without reference standards. dPCR delivers high precision for low-level mosaicism detection and validation of subtle single-exon CNVs.
Fluorescence In Situ Hybridization (FISH)
FISH uses labeled DNA probes hybridized to chromosome preparations or interphase nuclei to visualize copy number at specific loci. It remains valuable for detecting amplifications such as HER2 and MYCN, and for characterizing complex structural rearrangements, though its resolution is limited to probes of approximately 100 kb or larger.
Applications
Clinical Genetics and Rare Disease Diagnosis
CNV detection is a first-tier diagnostic test for patients with unexplained developmental delay, intellectual disability, autism spectrum disorder, epilepsy, and multiple congenital anomalies. Chromosomal microarray analysis identifies pathogenic CNVs in 10-20% of these patients, substantially exceeding the diagnostic yield of conventional karyotyping.
Prenatal and Preimplantation Genetic Testing
In prenatal settings, CNV analysis is applied to amniotic fluid and CVS samples following abnormal ultrasound findings or positive screening results. Non-invasive prenatal screening using maternal cfDNA enables genome-wide aneuploidy and selected microdeletion detection without procedural risk. Preimplantation genetic testing (PGT-SR) evaluates structural rearrangements and CNVs in embryos generated through IVF.
Oncology and Precision Medicine
CNV biomarkers guide targeted therapy selection and prognosis across multiple cancer types. HER2 amplification determines eligibility for anti-HER2 therapies, EGFR and MET amplification inform lung cancer treatment, and MYCN amplification stratifies neuroblastoma risk. Genome-wide copy number profiling also supports tumor classification and research into cancer evolution.
Carrier Screening and Reproductive Health
CNV detection forms part of expanded carrier screening panels, identifying dosage changes in genes such as SMN1 (spinal muscular atrophy) and CYP21A2 (congenital adrenal hyperplasia) that inform reproductive risk for prospective parents.
Pharmacogenomics
Gene copy number directly affects drug metabolism capacity. CYP2D6 duplications confer ultrarapid metabolizer status, impacting dosing for antidepressants, opioids, and tamoxifen. CNV testing supports personalized medication selection and dosing optimization.
Research and Biotechnology
CNV analysis is extensively applied in genome-wide association studies, agricultural genomics for breeding trait loci, cell line authentication, biopharmaceutical production cell bank characterization in compliance with regulatory expectations, and population genetics research.
FAQ
What is the difference between CNV detection and karyotyping?
Conventional karyotyping examines chromosomes under a microscope and can detect abnormalities larger than approximately 5-10 Mb. CNV detection methods such as chromosomal microarray and NGS achieve resolutions of 10-100 kb, enabling identification of submicroscopic deletions and duplications invisible to karyotyping. However, balanced translocations and inversions are not detectable by array-based CNV analysis, so the methods are complementary.
Which CNV detection method should I choose?
Method selection depends on the clinical question. For known single-gene disorders such as DMD, MLPA offers exon-level resolution at low cost. For genome-wide discovery in developmental disorders, chromosomal microarray or NGS-based approaches are preferred. For oncology biomarkers, qPCR, FISH, or NGS panels are standard. For prenatal screening, low-pass whole genome sequencing of cfDNA is the leading technology. Consultation with accredited laboratories helps match the platform to your specific requirements.
What sample quality is required for reliable CNV results?
Most CNV assays require high-quality genomic DNA with minimal fragmentation. Typical requirements include 200 ng to 1 µg of DNA, A260/A280 ratio between 1.8 and 2.0, and adequate molecular weight. FFPE-derived DNA may be partially degraded but remains suitable for validated assays such as MLPA and targeted NGS. Laboratories always perform DNA quantification and quality control before testing.
How long does CNV detection take?
Turnaround time varies by method. qPCR and MLPA results are typically available within 3-7 working days. Chromosomal microarray analysis usually requires 7-14 calendar days including interpretation. NGS-based workflows, including bioinformatics analysis and clinical reporting, generally take 10-20 working days. Urgent clinical situations such as prenatal diagnosis may qualify for expedited processing.
Can CNV detection identify all genetic diseases?
No single technology detects all variant types. CNV detection focuses on copy number changes but does not reliably identify single nucleotide variants, small insertions/deletions, repeat expansions, methylation abnormalities, or balanced rearrangements. Comprehensive genetic evaluation often combines CNV analysis with sequencing technologies, methylation testing, and karyotyping depending on the clinical presentation.
Are CNV results always clinically actionable?
Not all detected CNVs are pathogenic. Many copy number changes represent benign polymorphisms found in healthy individuals. Classification follows international standards such as ACMG/AMP guidelines, which categorize CNVs as pathogenic, likely pathogenic, uncertain significance (VOUS), likely benign, or benign. Variant interpretation incorporates databases such as ClinGen, DECIPHER, and gnomAD-SV, parental testing, and published evidence. Genetic counseling is strongly recommended for result interpretation and family planning.
How is quality assurance maintained in CNV testing?
Accredited third-party laboratories maintain quality systems compliant with ISO 15189 or ISO/IEC 17025 requirements. Quality measures include validated analytical workflows, participation in external quality assessment (EQA) schemes and proficiency testing programs, documented standard operating procedures, orthogonal confirmation of reportable findings, continuous competency assessment of personnel, and comprehensive audit trails from sample receipt to final reporting.